Shares of Y-mAbs Therapeutics, Inc (NASDAQ: YMAB) seem undervalued, given the market opportunities of the company’s core, late stage assets as well as upside potential from its label expansions and earlier-stage pipeline efforts, according to Wedbush.
Wedbush’s David Nierengarten initiated coverage of Y-mAbs Therapeutics with an Outperform rating and a price target of $38.
Markets are likely to become increasingly volatile over the next 12 months, due to macroeconomic and political factors. Against this backdrop, stocks like Y-mAbs Therapeutics, which have advanced assets as well as upside potential, should be “particularly attractive for investors,” Nierengarten said in the initiation note.
Two of the company’s lead candidates, naxitamab and radiolabeled 131I-omburtamab, have exhibited positive results in patients with neuroblastoma.
The analyst expects the Biologics License Application (BLA) filings, both of which are scheduled for the fourth quarter, to be successful and for both candidates to be approved in 2020.
Y-mAbs has label expansion opportunities in the near term, into front-line high risk and retreating neuroblastoma for both the candidates and additionally osteosarcoma for naxitamab, Nierengarten mentioned.
The company’s pipeline includes a therapeutic cancer vaccine, bispecific antibody programs and Lu177-omburtamab. Y-mAbs earlier stage efforts, particularly radiolabeled Lu177-omburtamab, “could provide significant upside as it progresses through the clinic to treat B7-H3 positive CNS/LM (central nervous system / leptomeningeal metastasis) tumors in adults,” Nierengarten wrote.
Shares of Y-mAbs Therapeutics were up 168% to $25.91 Wednesday.
Latest Ratings for YMAB
|Sep 2019||Initiates Coverage On||Outperform|
|Apr 2019||Initiates Coverage On||Buy|
View More Analyst Ratings for YMAB
View the Latest Analyst Ratings
See more from Benzinga
- Conn's Prospects Are Bright, Boosted By Younger Stores, KeyBanc Says
- Wells Fargo Upgrades Emergent Biosolutions After Smallpox Vaccine Announcement
- MKM: Bloomin' Brands Optimism May Increase With This Activist Investor Taking A Stake
© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.